Designing treatment plans for NSCLC patients hinges upon molecular profiling and PDL1 testing, guiding the administration of receptor monoclonal antibodies (mAb) or small-molecule TKIs tailored to the specific driver mutation [29,30]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.